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AbstrAct:
MDM2 plays a key role to physiological processes like growth arrest, senescence 
and apoptosis. It binds to and inhibits key proteins like p53 and the RB protein, 
and MDM2 amplification as well as protein overexpression without amplification is 
seen in many solid tumors. An MDM2 promoter polymorphism (SNP309T>G) has 
been found associated with enhanced Sp1 transcription factor binding and elevated 
MDM2 transcription. While 309G has been found associated with elevated cancer 
risk and young age at diagnosis of different cancers, results in Caucasians have 
been  at  variance.  Recently,  we  reported  a  second  polymorphism  (SNP285G>C) 
located on the 309G allele. The 285C/309G haplotype accounts for about 12% of 
all 309G alleles among Norwegians, Dutch and British habitants. Assessing Sp1 
binding to the MDM2 promoter using surface plasmon resonance technology, we 
found SNP309G to enhance Sp1 binding by 22% while SNP285C reduced Sp1 
binding by 51%. SNP285C reduced the risk of breast cancer and ovarian cancer 
among 309TG/309GG carriers by 21 and 26%, respectively, but in particular the 
risk of ovarian cancer among 309TG heterozygotes (reduction by 37%). The fact 
that the 285C/309G haplotype accounted for only 1.9% of all 309G alleles among 
Finns and was absent in Chinese indicate 285C to be a young polymorphism. 
Murine Double Minute Clone 2 (MDM2) plays a 
key role in the regulation of cell cycle and apoptosis. The 
MDM2 gene was originally discovered and cloned from a 
spontaneously transformed BALB/c 3T3 mouse cell line 
[1], and it was later shown to act as an oncogene in nude 
mice [2]. The MDM2 protein acts as a p53 antagonist 
and is linked to p53 in a feedback-loop where p53 
enhances MDM2 transcription in response to genotoxic 
stress, whereas MDM2 binds to p53 and directs it for 
proteosomal degradation through ubiquitinylation [3, 4]. 
The vital importance of this MDM2 – p53 interaction is 
underlined by the fact that although MDM2 null mice 
uniformly die at an early embryonic stage, MDM2 / p53 
null double knock-outs are live born with no obvious 
developmental defects [5, 6]. 
MDM2, in addition, inactivates the retinoblastoma 
protein (pRB) by protein binding [7], preventing pRB 
from binding and inactivating E2F1. Further, it directly 
interacts with and stimulates E2F1 [8], a transcription 
factor with complex functions, both able to promote cell 
cycle progression through induction of genes coding for 
e.g DNA polymerase and cyclin E but also apoptosis 
through induction of genes coding for e.g. APAF1 and 
caspases [9]. The fact that MDM2 acts as a key regulator 
of both the p53 and the pRb functional pathways points 
to MDM2 as a “master” gene potentially governing the 
balance between cellular processes like continued growth, 
growth arrest, senescence and apoptosis. 
somAtic AlterAtions of MDM2 in 
mAlignAnt tumors
So far, very few somatic mutations in the MDM2 
gene has been identified. The gene however, has been 
found  amplified  in  many  tumour  forms  [reviewed  in 
10]. In addition, several tumors reveal elevated staining 
for the MDM2 protein despite harbouring a normal Oncotarget 2011; 2:  251 - 258 252 www.impactjournals.com/oncotarget
gene copy number. Thus, several mechanisms apart 
from  MDM2  gene  amplification  has  been  suggested 
to  influence  MDM2  levels  and  activity.  These  include 
enhanced translation through increased activity of BCR/
ABL [11-13] and expression of a variety of alternatively 
or aberrantly spliced MDM2 mRNA variants [14]. While 
splice variants have been reported to inhibit the function 
of wild-type MDM2 through dimerization [15, 16], 
the full function of these alternatively spliced mRNAs 
remains to be elucidated. Recently, another alternative 
mechanism of MDM2 upregulation, disturbing proper 
function of the p53 pathway, was reported: Inuzuka and 
co-workers demonstrated that MDM2 is phosphorylated 
by Casein Kinase I (CKI), marking the MDM2 molecule 
for degradation via the SCFβ-TRCP Ubiquitin ligase [17]. 
This has been suggested as a potential mechanism of 
MDM2 upregulation in cases where CKI and / or β-TRCP 
are inactivated [18], a hypothesis that is supported by the 
findings of β-TRCP-deletions in several tumor forms [18-
20].
germ line AlterAtions of MDM2 
function.
Despite its role as a proto-oncogene, so far, neither 
MDM2 germ line mutations nor increased gene copy 
number at the germ line level has been identified in cancer 
prone families. Thus, one may speculate whether loss of 
MDM2 function through deleterious mutations may be 
incompatible with life, resembling the effect in MDM2 
null mice. 
The MDM2 gene contains two main promoters; the P1 
located upstream of exon 1, and the intronic P2 promoter, 
located between exon 1 and exon 2. P1 is considered 
responsible for regulating MDM2 expression levels in the 
“non-stressed” setting. This promoter contains a binding 
site for PTEN, which has been shown to suppress MDM2 
expression. The P2 promoter is considered to be more 
inducible and regulates MDM2 level in response to cellular 
stress and stimulation by different ligands including p53, 
Sp1 and the estrogen receptor (Figure 1) [21, 22]. 
In 2004, the group lead by Arnold Levine identified 
a polymorphism SNP309 (T>G; rs2279744) in the P2 
promoter [21]. The G-allele is found across all ethnic 
groups albeit at a variable frequency (~10% of MDM2 
alleles among African Americans, 40% in Caucasians 
and 50% in Asians) [23]. It was found to increase the 
expression levels of MDM2  through enhancing the 
binding of the Sp1 transcription factor. The G-allele was 
linked to early age at cancer diagnosis among individuals 
with Li-Fraumeni syndrome (carrying germline TP53 
mutations) and an early age at diagnosis of soft tissue 
sarcomas, large B-cell lymphomas and colorectal cancers 
in women not diagnosed with any cancer predisposing 
germline mutations [21, 24]. In addition, an early 
diagnosis of estrogen receptor rich (defined as >50% of 
cells revealing positive ER staining) but not receptor-
poor breast cancer was recorded [21]. Although these data 
are strongly supported by the finding that MDM2SNP309G/G 
mice are more tumor prone than MDM2SNP309T/T mice 
[25], case control studies across many tumor forms and 
ethnic groups have provided conflicting results regarding 
the role of the SNP309G-allele as a cancer risk factor 
in humans [23, 26]. Notably, so far most of the studies 
linking the SNP309G variant allele to enhanced cancer 
risk or a young age at diagnosis have been performed 
figure 1: MDM2 promoter P2. This promoter is located between the exons 1 and 2 of the MDM2 gene and is induced upon cellular stress. 
Promoter P2 harbors binding sites for among others p53 and Sp1. SNP285 and SNP309 are both located within the latter binding sites.
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on Asian or Ashkenazi Jewish populations [23, 26]. In 
contrast, the majority of studies performed in Caucasians 
are negative [23, 26]. In addition to SNP309, several 
other SNPs have also been reported both in the promoter 
P2 area and the rest of the MDM2 gene. Notably, in the 
three most thoroughly studied ethnic groups (Caucasians, 
African Americans and Ashkenazi Jews) the variability in 
other polymorphic sites is much higher for the SNP309T-
allele than for the G-allele [27]. Taken together with the 
relatively high frequency of SNP309G, this may indicate 
a positive selection pressure for the G-variant. Notably, 
the reported polymorphisms in the MDM2 gene are 
restricted to either SNP309T or G, indicating that they 
are of younger origin than the 309 variation. To this day, 
potential biological function of these polymorphisms 
remains to be elucidated. 
snP285c reduces the risk of 
breAst And ovAriAn cAncer
Studying the potential effects of MDM2 promoter 
SNP’s on breast cancer therapy, outcome and prognosis, 
we, concomitantly with a Scottish group [28], discovered 
a second promoter P2 polymorphism, 285G>C, located 
24 bps from SNP309 (Figure 2) [29]. The C-variant of 
SNP285 is located on the SNP309G allele forming a 
distinct SNP285C/309G haplotype. Notably, SNP285C 
was found at a similar frequency (average of 7.8% of 
individuals) in different Western populations (Dutch, 
British, Norwegian) but was absent from Asians (Chinese). 
Interestingly, the frequency of this polymorphism among 
Finnish individuals living in the Helsinki area (1.6%), was 
significantly lower compared to the frequency observed 
among other Western Europeans. Potential interpretations 
of this finding is discussed below. 
Using the highly sensitive surface Plasmon 
resonance technology (SPR), we confirmed the previous 
findings of Bond et al [21] that the SNP309G-allele had a 
stronger binding affinity to the Sp1 transcription factor as 
compared to the SNP309T-allele (22% increase in binding 
strength).  In  contrast,  SNP285C  significantly  reduced 
Sp1-binding to the MDM2 promoter (51% decreased 
binding strength). Importantly, the combined SNP285C / 
SNP309G haplotype (which accounts for about 12% of all 
309G alleles in Caucasians) had a reduced affinity towards 
Sp1 as compared to the “wild-type” SNP285G/309T 
haplotype (>10% decreased binding strength) [29]. While 
secondary mutations antagonizing a primary mutation in 
BRCA2 through excision of the mutated area has been 
shown to revert platinum drug sensitivity in breast as 
well as ovarian carcinomas [30, 31], to the best of our 
knowledge, secondary SNP’s antagonizing the effect of a 
previous SNP on the same gene, have not previously been 
reported (Figure 3).
In line with the finding of reduced binding strength 
to the Sp1 transcription factor and, thereby, reduced 
transcription, we found the presence of SNP285C to be 
associated with significantly lowered risk of both breast 
and ovarian cancer. Among individuals potentially 
harbouring the SNP285C variant (carriers of SNP309G) 
we found a 21% reduced risk of breast cancer among 
individuals carrying SNP285C as compared to those 
homozygous for SNP285G. Regarding ovarian cancer 
figure 2: snP285 and snP309 genotypes. Electropherograms showing the four different genotypes of the Sp1-binding elements of 
MDM2 promoter P2 commonly observed among Caucasians. (Electropherograms display sequence as reverse complementary to the open 
reading frame of MDM2) 
A   309TT / 285GG B   309TG / 285GG
C   309GG / 285GG D   309TG / 285GCOncotarget 2011; 2:  251 - 258 254 www.impactjournals.com/oncotarget
risk, the effect was even stronger. Here, the presence of 
a SNP285 allele lead to a reduction in risk of disease 
of 26%. Among individuals carrying the SNP309TG 
heterozygous genotype, SNP285C reduced the risk of 
ovarian cancer by 37%, while no effect was observed in 
SNP309GG homozygotes. In contrast, the effect of 285C 
on breast cancer risk was most profound in SNP309GG 
homozygotes (reduction of 45%), with a small non-
significant reduction of 9% in SNP309TG heterozygotes.
The data for ovarian cancer patients fits well with 
the in vitro data and a hypothesis that one SNP285C may 
counteract and neutralize the effect of one SNP309G, but 
not two SNP309Gs. The results from the breast cancer 
cohorts may seem somewhat harder to understand; notably, 
it is well known from other genes that heterozygote 
carriers of a genetic alteration may be at risk of different 
diseases than the homozygotes [32].
The  finding  that  the  SNP285C/309G  haplotype 
accounted for about 12% of all SNP309G alleles among 
Caucasians may be of importance explaining the potential 
difference regarding the effect of SNP309 status on 
cancer risk among Caucasians versus Asians [23, 26]. 
While studies on Asian populations may represent the 
“true” effect of SNP309G, studies on Caucasians may 
need to be corrected for the presence on of the SNP309G-
counteracting SNP285C in order to unmask the real effect 
of SNP309G in these populations.
Importantly, so far the potential effect of SNP285C 
on the risk of malignancies other than breast and ovarian 
cancer has not been explored. Considering other risk 
modulating factors associated with breast and ovarian 
cancers, notably both diseases are found at high incidence 
among individuals carrying pathogenic BRCA1  and 
BRCA2 germline mutations. However, this does not 
mean that breast and ovarian cancer have a particular and 
common etiology indicating that the effect of SNP285C 
may be restricted to these two malignancies. For example 
estrogen exposition is a major risk factor associated with 
breast but not ovarian cancer [33]. Thus, it may well be that 
SNP285C modulate the risk of several other malignancies 
in addition to breast and ovarian cancer 
evolutionAry selection of MDM2 
snPs
Examining  MDM2 haplotype status across 
ethnic groups, Atwal and colleagues recorded multiple 
polymorphisms with an ethnic diversity between 
Caucasians (general population), Ashkenazi Jews and 
American-Africans [27]. They found a single SNP309G 
haplotype in Africans and Caucasians, but two additional 
309G-linked polymorphisms in Ashkenazi’s. In contrast, 
multiple SNPs were recorded on the T-allele, mostly 
located outside the promoter area and outside the exons. 
However, except for the SNP309G and now SNP285C, the 
potential functional role of the different polymorphisms 
figure 3: impact of snP309 and snP285 on mdm2 transcription. Presence of the SNP309G-variant (red) enhances the binding 
strength between MDM2 promoter P2 and the transcription factor Sp1, thus, leading to increased MDM2 transcription as compared to the “wild-
type” SNP309T-variant. The effect of the SNP285C-variant (green) is the opposite, reducing the binding strength for Sp1, thus, also reducing 
the level of MDM2 transcription as compared to the “wild-type” SNP285G-variant. The effect of SNP285C is stronger than SNP309G, thus, 
presence of the SNP285C/309G haplotype leads to reduced MDM2 transcription as compared to the “wild-type” SNP285G/309T haplotype.
ACGGGGGCCGGGGGCTGCGGGGCCGCTTCGG
ACGGGGGCCGGGGGCTGCGGGGCCGCTGCGG
ACGCGGGCCGGGGGCTGCGGGGCCGCTGCGG
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have not been determined. Thus, we may not at this stage 
speculate on potential reasons for evolutionary selection 
(if any) for these additional SNP’s.
The variable distribution of SNP309G and, now, in 
particular the SNP285C, across ethnic groups may lead 
to speculations on the phylogenetic selection of these 
particular MDM2 variants. Considering the key role of 
MDM2  influencing  the  p53  as  well  as  retinoblastoma 
pathway, naturally a fine tuning of its biological activity 
must be of critical importance, as documented by the 
influence of SNP285/309 haplotype status on cancer risk. 
These observations raise further important questions. 
Considering SNP309G, this variant enhances MDM2 
transcription, subsequently antagonising p53 function. 
The fact that the SNP309G genotype has been found 
associated with increased cancer risk as well as an early 
cancer diagnosis [21, 26] may suggest a negative selection 
for this variant. However, with a few exceptions solid 
tumours in general are diagnosed after the age of child-
birth. Thus, early death related to malignant disease is 
unlikely to explain evolutionary selection of the SNP309 
variants. 
Regarding the p53 Pro72Arg polymorphism, the 
Arginine variant has been shown to reveal stronger pro-
apoptotic effects as compared to the Proline allele [34]. 
In Africa, the p53 proline variant becomes more frequent 
approaching the equatorial line [35], and Atwal et al 
postulated that a high frequency of MDM2 SNP309T 
among Africans may act in concert balancing a weaker 
p53 codon 72 proline variant [27]. So far however, 
we know the frequency of the MDM2 SNP309T and 
G variants among American Africans only; thus, to 
confirm such a hypothesis, assessing the SNP309 status 
across different geographical and ethnic groups in 
Africa is warranted. Further, studies on the distribution 
of SNP309G across different areas in Africa as well as 
in Asia may add important information with respect to 
potential mechanisms selecting for this polymorphism in 
general. While Fang et al, in two small studies, reported 
MDM2 SNP309G to be associated with increased risk of 
missed abortion among Han Chinese [36, 37], this finding 
needs to be confirmed in larger studies involving other 
ethnic groups as well. 
We do not know the phylogenetic age of either the 
SNP309G or the SNP285C polymorphism, but some 
assumptions may be made. The fact that SNP309G exists 
in all ethnic groups (albeit at different incidence) indicates 
this variant to be an ancient polymorphism, while  the 
figure 4: distribution of snP285c among different ethnic groups. SNP285 is observed among ~8% of British, Dutch and Norwegians 
and in ~2% of Finns, while it is absent in Chinese. The presence of SNP285C only among Caucasians indicates that this polymorphism has 
originated after the separation of Caucasians and Asians approximately 60,000 years ago, but studies on other European populations are 
warranted to shed light on the origin of SNP285C. Most likely, SNP285C should be absent in all ethnic groups in the Middle-East, but this has 
yet to be confirmed.
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fact that SNP285C locates to the SNP309G allele and is 
absent in Han Chinese, indicates SNP285C to be a young 
polymorphism, appearing in Caucasians after the “out of 
Africa” migration and after separation of the Caucasian 
and the Asian populations (Figure 4). Further, the fact that 
SNP285C is found at a low frequency (1.6%) among Finnish 
habitants, is interesting. The genetic heritage of the Finns 
is incompletely understood; while their language, similar 
to that of the Lapps, Estonians and Hungarians belongs 
to the family of Finno-Uralic languages [38], there is 
evidence suggesting a more complex genetic background 
of the population [39], including Y-chromosome 
migration from Asia [40]. Notably, European migration 
started out from a few “sanctuaries” at the end of the last 
ice age about 10.000 years ago. While the first Finnish 
settlements can be dated around that time [41], there is 
evidence suggesting the Finnish population may have 
gone through a “bottleneck” 2-4000 years ago [42, 43], 
and the Finnish population is characterized by a spectrum 
of recessive diseases consistent with genetic isolation [41, 
44]. Thus, the finding of a low incidence of the SNP285C 
in the Finnish population may have several explanations: 
It may have been absent in the original population and 
come along through subsequent immigration; thus, 
there is evidence for a second major immigration about 
2000 years ago [44]. Further, as the Finnish subjects 
analysed so far, were collected from the Helsinki area, 
the polymorphism may also have been brought in through 
more recent immigrants from other European countries 
like Sweden. Both hypothesis implicates SNP285C may 
have arisen after separation of the Finnish ancestors from 
the main immigrants into Western Europe. In contrast, the 
possibility exist that SNP285C occurred at an incidence 
of about 1.6% among Europeans in general 2-4000 
years ago. Thereafter, it has expanded through selection 
pressure in the general European population but, for 
reasons unexplained, not within the Finnish population.
To possibly date the origin of the 285C 
polymorphism, there is a need to study the distribution 
of the SNP285C across additional European populations, 
including Estonians and Hungarians in particular, as 
well as other European “isolated” populations that have 
gone through genetic “bottle-necks”, like the Basques 
and Sardinians [45]. Whatever its exact age may be, its 
spread in Western European populations strongly suggests 
a positive selection pressure. As argued with respect to 
SNP309G, the effect of SNP285C on cancer risk may 
probably not explain evolutionary selection for this 
variant in Caucasians.
While there seems to be a positive selection for 
SNP309G in the Caucasian as well as Asian ethnic 
groups, it is remarkable with a subsequent selection for the 
SNP285C, antagonizing SNP309G, among Caucasians. 
However, the Western European population has passed 
through distinct evolutionary “bottle-necks” during 
history. At the end of the ice age, only a limited number of 
Europeans survived in certain “refugees” like in Northern 
Spain, Ukraine and Moldovia [46]. As for more recent 
times, the black plague eradicated between one half and 
two-thirds of the European population between 1346-50. 
Further, during the 10-12.000 years passing since the last 
ice age, there has been severe climate alterations, causing 
substantial changes in the living conditions in general. It 
is not unlikely that fine-tuning of MDM2 levels, like the 
balance between SNP309 and SNP285 status, may have 
provided survival advantages under some stages of these 
shifting conditions.
Understanding the mechanisms of evolutionary 
selection for MDM2 SNP309G as well as SNP285C may 
add important information to our understanding of the role 
of this complicated gene in human biology.
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